United States - English - NLM (National Library of Medicine)

direct_rx - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - hypertension metoprolol tartrate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. angina pectoris metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. myocardial infarction metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol tartrate. oral metoprolol tartrate therapy can be initiated after intravenous metoprolol tartrate therapy, or alternatively, oral treatment can begin within 3 to 10 days of acute event(see dosage and administration, contraindications, and warnings). hypertension and angina metoprolol tartrate is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta-blockers (cross sensitivity between beta-blockers can occur). sick-sinus syndrome. severe peripheral arterial circulatory disorders. myocardial infarction metoprolol is contraindicated in patients with a heart rate < 45 beats/min; second- and third-degree heart block; significant first-degree heart block (p-r interval ³ 0.24 sec); systolic blood pressure < 100 mmhg; or moderate-to-severe cardiac failure (see warnings).

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - metoprolol 100 mg - metoprolol succinate extended-release tablets, usp are indicated for the treatment of  hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmaco

Canada - English - Health Canada

apotex inc - metoprolol tartrate - tablet - 50mg - metoprolol tartrate 50mg - beta-adrenergic blocking agents

Canada - English - Health Canada

apotex inc - metoprolol tartrate - tablet - 100mg - metoprolol tartrate 100mg - beta-adrenergic blocking agents

Canada - English - Health Canada

apotex inc - metoprolol tartrate - tablet - 100mg - metoprolol tartrate 100mg - beta-adrenergic blocking agents

Canada - English - Health Canada

apotex inc - metoprolol tartrate - tablet - 50mg - metoprolol tartrate 50mg - beta-adrenergic blocking agents

Canada - English - Health Canada

apotex inc - metoprolol tartrate - tablet - 25mg - metoprolol tartrate 25mg - beta-adrenergic blocking agents

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - metoprolol tartrate 100mg - film coated tablet - 100 mg - active: metoprolol tartrate 100mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose purified talc sodium starch glycolate starch titanium dioxide - disturbances of cardiac rhythm, including supraventricular and ventricular arrhythmias.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - metoprolol tartrate 50mg - film coated tablet - 50 mg - active: metoprolol tartrate 50mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide red lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose purified talc sodium starch glycolate starch titanium dioxide - disturbances of cardiac rhythm, including supraventricular and ventricular arrhythmias.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 50 mg - metoprolol tartrate tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. metoprolol tartrate tablets, usp are indicated in the long-term treatment of angina pectoris. metoprolol tartrate tablets, usp are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see dosage and administration , contraindications , and warnings ). metoprolol tartrate is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings ). hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur